ELCC 2018 | Key findings of the ALEX study: Improved therapeutic options for ALK-positive NSCLC

The key findings of the anaplastic lymphoma kinase-positive non-small cell lung cancer (ALEX) study (NCT02075840) have established alectinib as a key treatment compared with crizotinib. In this talk, Solange Peters, MD, PhD, from the University of Lausanne, Lausanne, Switzerland, discusses the implications with a new treatment and how alectinib proves to be a superior treatment strategy with regards to these implications. This video was recorded at the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland.